The Impact of Mesenchymal Stem Cell Therapy on Cognitive Performance in People Living with Multiple Sclerosis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

Click here to download the PDF file.


Abu-AlHawa, Maha




In Multiple Sclerosis (MS), cognition is directly affected by neural integrity and secondary disease characteristics (anxiety, depression and fatigue). Mesenchymal stem cell therapy (MSCT) has been recently studied due to its potential for neural repair in MS. It is hypothesized that cognitive improvement will be seen after MSCT. The change in cognition is expected to be correlated with changes in secondary disease characteristics and neurophysiological measures (neural conduction time). Ten participants received MSCT. Cognition, secondary disease characteristics, and conduction time were evaluated pre- and post- (12 month) therapy. Eight participants demonstrated cognitive improvement in at least one test. Secondary disease characteristics and conduction time were not associated with cognition in our sample. In conclusion, MSCT appears to be safe with regards to cognition and does not worsen secondary disease characteristics. Future efficacy studies have the potential to show greater cognitive improvement than the current preliminary study.


Psychology - Cognitive
Mental Health




Carleton University

Thesis Degree Name: 

Master of Cognitive Science: 

Thesis Degree Level: 


Thesis Degree Discipline: 

Cognitive Science

Parent Collection: 

Theses and Dissertations

Items in CURVE are protected by copyright, with all rights reserved, unless otherwise indicated. They are made available with permission from the author(s).